Market Access and Reimbursement Risk Assessment.
Built by former payers, HTA reviewers, and Industry Experts.
Datopotamab deruxtecan — complimentary MARA Rating report cover: pricing & reimbursement risk assessment for metastatic breast cancer. Datopotamab deruxtecan has been assessed using the MARA Rating framework for its role
Ensifentrine – complimentary MARA Rating report: pricing & reimbursement risk assessment for COPD maintenance therapy. Ensifentrine, marketed as Ohtuvayre, has been reviewed under the MARA Rating system. This assessed its
Nipocalimab – complimentary MARA Rating report: pricing & reimbursement risk assessment for generalized myasthenia gravis. This MARA Rating® complimentary report provides a market-access risk assessment of Nipocalimab for the treatment
Suzetrigine – complimentary MARA Rating report: pricing & reimbursement risk assessment for neuropathic pain. This complimentary MARA Rating® report reviews Suzetrigine’s access profile in the treatment of neuropathic pain. The
Tolebrutinib – complimentary MARA Rating report: pricing & reimbursement risk assessment for secondary progressive multiple sclerosis. This complimentary MARA Rating® report examines Tolebrutinib’s market-access risk profile for treating non-relapsing secondary
Survodutide – complimentary MARA Rating report: pricing & reimbursement risk assessment for obesity treatment. This complimentary MARA Rating® report assesses Survodutide’s market-access risk profile for the treatment of obesity. The
Retatrutide – complimentary MARA Rating report: pricing & reimbursement risk assessment for obesity and metabolic disorders. This complimentary MARA Rating® report assesses Retatrutide for obesity with or without metabolic disorders.
Orforglipron – complimentary MARA Rating report: pricing & reimbursement risk assessment for obesity and type 2 diabetes. This complimentary MARA Rating® report reviews Orforglipron’s market-access profile for the treatment of
Brensocatib – complimentary MARA Rating report: pricing & reimbursement risk assessment for non-cystic fibrosis bronchiectasis. Brensocatib has undergone evaluation through the MARA Rating framework to assess its market-access prospects for